|Bid||2.41 x 2900|
|Ask||3.00 x 1100|
|Day's Range||2.4500 - 2.5500|
|52 Week Range||1.8500 - 3.4000|
|Beta (3Y Monthly)||2.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 5, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.25|
April 1, 2019 PDUFA date for Gimoti™ NDA Cash runway extended through June 2019 SOLANA BEACH, Calif., Nov. 13, 2018 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty.
If you want to know who really controls Evoke Pharma Inc (NASDAQ:EVOK), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions as Read More...
Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.
The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.
Evoke Pharma Inc (NASDAQ:EVOK), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM over the last few months. WithRead More...
Evoke Pharma Inc’s (NASDAQ:EVOK): Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. On 31 December 2017,Read More...
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Evoke Pharma, Inc. (NASDAQ: EVOK ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018 at 4:30 PM Eastern Time. To ...